Nova Patents
IS6202A

Pharmaceutical formulations and methods comprising intranasal morphine

Abstract

This record has no abstract on file.

Term

Term ended

Projected expiry passed 14 December 2021, 4.8 years ago.

  1. Priority
  2. Filed and published
  3. Projected expiry
  4. Today

42 members in 30 offices

This recordMember, by publication datePriority claim20 more offices are in the list below

Priority claims7

Priority claims
DocumentOfficeKindDate
33453799United States of AmericaA
33453799United States of AmericaA
0014157United States of AmericaW
0014157United States of AmericaW
PCTUS0014157–––
US19990334537–––
WO2000US14157–––

Members42

Family members, oldest first
DocumentOfficeKind
CA2374877A1CanadaA1
WO0076506A1World Intellectual Property Organization (WIPO)A1
AU5156100AAustraliaA
NO20015931D0NorwayD0
DK200101859ADenmarkA
IS6202AThis recordIcelandA
SE0104203D0SwedenD0
FI20012462AFinlandA
GB0128383D0United KingdomD0
LU90859B1LuxembourgB1
NO20015931LNorwayL
EP1183027A1European Patent Office (EPO)A1
KR20020016831ARepublic of KoreaA
GB2367005AUnited KingdomA
BR0012082ABrazilA
CZ20014399A3CzechiaA3
SK18172001A3SlovakiaA3
LT2001119ALithuaniaA
BG106221ABulgariaA
DE10084709T1GermanyT1
HUP0201856A1HungaryA1
SI20850ASloveniaA
LV12859BLatviaB
LT4976BLithuaniaB
JP2003501467AJapanA
EP1183027A4European Patent Office (EPO)A4
EE200100677AEstoniaA
HRP20010926A2CroatiaA2
SE0104203LSwedenL
MXPA01012879AMexicoA
PL352556A1PolandA1
ES2197792A1SpainA1
US6677346B1United States of AmericaB1
EE200300555AEstoniaA
CA2374877CCanadaC
EP1419774A1European Patent Office (EPO)A1
NZ515783ANew ZealandA
AU774175B2AustraliaB2
TR2001003613T2TürkiyeT2
TR200103613T2TürkiyeT2
HUP0201856A3HungaryA3
ES2197792B1SpainB1